NVO Novo Nordisk A/S
- Official Name: Novo Nordisk A/S
- Headquarters: 800 Scudders Mill Road, PLAINSBORO, NJ 08536, US
- CEO: Lars Jorgensen
- Website: novonordisk.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-15 | 1 | Lost by 2.564 | (1.182) - 1.382 | ||
| 2025-07-15 | 1R | Lost by 1.938 | (2.019) - (0.081) | ||
| 2025-07-16 | 1R | Lost by 1.386 | (0.444) - 0.942 | ||
| 2025-07-22 | 2 | Lost by 3.178 | (2.159) - 1.019 | ||
| 2025-07-29 | 3 | Lost by 14.791 | (13.934) - 0.857 | ||
| 2025-08-05 | 4 | Won by 15.265 TOTW | 16.343 - 1.078 | ||
| 2025-08-12 | 5 | Won by 8.446 | 9.709 - 1.263 | ||
| 2025-08-19 | 6 | Won by 5.511 TOTW | 10.297 - 4.786 | ||
| 2025-08-26 | 7 | Won by 1.063 | 0.879 - (0.184) | ||
| 2025-09-02 | 8 | Lost by 0.650 | 1.874 - 2.524 | ||
| 2025-09-09 | 9 | Lost by 0.558 | (4.801) - (4.243) | ||
| 2025-09-16 | 10 | Won by 5.861 TOTW | 6.228 - 0.367 | ||
| 2025-09-23 | 11 | Won by 5.538 | 3.997 - (1.541) | ||
| 2025-09-30 | 12 | Lost by 11.395 | (7.175) - 4.220 | ||
| 2025-10-07 | 13 | Won by 5.969 | 5.887 - (0.082) | ||
| 2025-10-14 | 14 | Lost by 8.376 | (4.073) - 4.303 | ||
| 2025-10-21 | 15 | Lost by 2.487 | (3.541) - (1.054) |
Latest News
Benzinga - 2026-10-23
Novo Nordisk's Awiqli Receives FDA Approval As The First And Only Once-Weekly Insulin For Children 10 Years Of Age And Older With Type 2 Diabetes
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-once-weekly-insulin-type-2-diabetes-mellitus-pediatric-patients
Benzinga - 2026-10-23
More Americans Now Take GLP-1 Drugs for Weight Loss Than Diabetes as Food, Alcohol and Apparel Habits Shift, Survey Finds
GLP-1 users cut sweets and switch clothing sizes as weight management becomes top use.
Benzinga - 2026-10-23
'Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption' - Reuters
https://www.reuters.com/legal/litigation/dr-reddys-rolls-out-new-generic-ozempic-brands-amid-obeda-supply-disruption-2026-10-23/
Yahoo - 2026-10-22
Novo Nordisk (CPSE:NOVO B) Deepens AI Drug Discovery Ties
Novo Nordisk (CPSE:NOVO B) uses OpenAI’s Rosalind AI model in its drug discovery work, tying its R&D to OpenAI’s tech stack. OpenAI has acquir...
Yahoo - 2026-10-22
Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances
Roche's sales rise 6% at constant exchange rates in the first nine months of 2026, as key drug growth offsets legacy product declines and pipelin...
Yahoo - 2026-10-22
NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains?
Viking Therapeutics' late-stage obesity drug and promising weight-maintenance data could offer greater upside than Novo Nordisk, despite higher c...
Yahoo - 2026-10-22
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility
Bristol Myers Squibb has led in seven of eight quarters, but Novo Nordisk's recent spike signals a shift worth watching for income-focused invest...
Yahoo - 2026-10-21
Where Will Novo Stock Be in 10 Years?
The company may lean on its core therapeutic area to help it overcome recent headwinds.
Yahoo - 2026-10-21
European Equities Traded in the US as American Depositary Receipts Track Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were climbing higher late Wednesd
Yahoo - 2026-10-21
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
NVO's Ozempic and Wegovy sales will be in focus for Q3 results as oral GLP-1 launches expand, while pricing pressure and competition challenge gr...
Yahoo - 2026-10-21
Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss
Novo Nordisk's CagriSema delivers 25% weight loss in women, spotlighting three ETFs for diversified exposure to the sector's growth.
Yahoo - 2026-10-21
Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock?
Its leading investigational drug demonstrated relatively high levels of weight loss in a late-stage clinical trial.
Yahoo - 2026-10-21
Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market
GLP-1 drugs are fueling a booming peptide market. Can the new PEPT ETF capitalize on rising demand and expanding medical applications?
Yahoo - 2026-10-21
Latest Wellness ETF Supplement: Peptides
Peptide and 'human enhancement' funds are joining a growing crowd of ETFs trying to capitalize off the wellness craze.
SeekingAlpha - 2026-10-20
Omeros: The Trade After European Rejection
Omeros Corporation is positioned to dominate the TM-TMA market with Yartemlea, the only FDA-approved therapy for this indication. See why I rate OMER ...
Yahoo - 2026-10-20
How Investors May Respond To Novo Nordisk (CPSE:NOVO B) Obesity Drug Competition
Novo Nordisk is pressing ahead with obesity and cardiometabolic drug development, including CagriSema regulatory submissions and a partnership with Pr...
Yahoo - 2026-10-20
OpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI says it's adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, and to its related Ros...
Yahoo - 2026-10-20
OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports
Investing.com -- OpenAI has acquired Orchestra Bio, a startup that builds AI agents to help pharmaceutical companies manage drug development, Axios re...
Yahoo - 2026-10-20
Prothena's Partnership Strategy: Growth Driver or Limitation?
PRTA's pharma partnerships offer $3 billion in potential milestone payments plus royalties, but clinical risks and partner control remain key cha...
Yahoo - 2026-10-20
If Eli Lilly Grows At 10% a Year, Here’s What $1,000 Becomes By 2030
Eli Lilly just posted 47.7% revenue growth and its weight-loss drugs are reshaping global healthcare, but whether that momentum turns a four-year inve...
Yahoo - 2026-10-20
Can Viking Therapeutics Carve Out a Place in the Obesity Market?
VKTX advances oral VK2735 into phase III as it explores weight maintenance and faces intensifying obesity drug competition.
Benzinga - 2026-10-20
Oracle Joins Forces With AstraZeneca to Put AI to Work in Drug Research
Oracle and AstraZeneca partner to advance AI-driven clinical trials, speed up recruitment, and connect research to patient care.
Yahoo - 2026-10-19
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why
In the most recent trading session, Novo Nordisk (NVO) closed at $38.42, indicating a -1.06% shift from the previous trading day.
Yahoo - 2026-10-19
Eli Lilly, IBD Stock Of The Day, Rides Foundayo, Medicare Bridge To Buy Point
Lilly rose 6.6% last week as Nvidia fell 6.6%. Coincidence?
Show more
Yahoo - 2026-10-19
Prediction: Eli Lilly Stock Could Be a Long-Term Winner for Investors
Yahoo - 2026-10-19
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market
Yahoo - 2026-10-19
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
Yahoo - 2026-10-19
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
Yahoo - 2026-10-19
Novo Nordisk A/S - share repurchase programme
Yahoo - 2026-10-18
Is Novo Nordisk (CPSE:NOVO B) Facing A Bigger Threat In Europe?
Yahoo - 2026-10-18
Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade?
Yahoo - 2026-10-16
Eli Lilly’s Growth Is Exceptional. Is Its Valuation Asking Too Much?
Yahoo - 2026-10-16
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
Yahoo - 2026-10-16
Novo Nordisk’s Growth Story Is Under Pressure as Eli Lilly Gains Ground
Yahoo - 2026-10-16
Lilly’s Foundayo wins EMA panel backing for obesity and type 2 diabetes
Yahoo - 2026-10-15
Viking Therapeutics Starts Phase III Development of Obesity Pill
Yahoo - 2026-10-15
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading
Yahoo - 2026-10-15
Walmart to increase employee benefits with new initiative for 2027
Yahoo - 2026-10-14
Novo Nordisk (NVO) Could Be 63% Undervalued Following Its Share Buyback
Yahoo - 2026-10-14
Roche Expands Obesity Pipeline With Rona's RNAi Candidate
Yahoo - 2026-10-14
Is Novo Nordisk (NYSE:NVO) A Long Term Value Opportunity Now?
Benzinga - 2026-10-14
QUICK SPARK: This New ETF Goes Beyond Eli Lilly, Novo Nordisk and Targets the Peptide Boom
Yahoo - 2026-10-14
Viking’s Key Obesity Pill Enters Phase 3 Trial – Here’s What Investors Need To Know
Yahoo - 2026-10-14
Ablexis Announce License Agreement with Novo
Yahoo - 2026-10-14
The Zacks Analyst Blog Highlights Walmart, Visa, Novo Nordisk, Village Super Market and Empire Petroleum
Yahoo - 2026-10-13
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo - 2026-10-13
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
Yahoo - 2026-10-13
Top Analyst Reports for Walmart, Visa & Novo Nordisk
Yahoo - 2026-10-13
Why A Biotech M&A Wave May Hit This Winter
Yahoo - 2026-10-13
Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued.
Yahoo - 2026-10-12
4 Healthcare Stocks Worth Owning for the Next Decade
Yahoo - 2026-10-12
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
Benzinga - 2026-10-12
BMO Capital Maintains Market Perform on Novo Nordisk, Lowers Price Target to $40
Yahoo - 2026-10-12
Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock?
Yahoo - 2026-10-10
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo - 2026-10-09
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Yahoo - 2026-10-09
Novo Nordisk (NVO) Raised Its Outlook, Then Aimed for Average Growth
Yahoo - 2026-10-09
Novo Nordisk (CPSE:NOVO B) Gets FDA Review Update As New EASD Data Land
Yahoo - 2026-10-09
Novo Nordisk stock target cut at Citi on lack of margin growth
Yahoo - 2026-10-08
Novo Nordisk’s CEO Was Asked Why His Stock Keeps Falling on Good News: ‘The Stock Market Is Always Right, but With a Bit of a Time Difference’
Yahoo - 2026-10-08
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?
Benzinga - 2026-10-08
Pharma Lobby Sues Trump Administration Over Medicare Drug Pricing Rule, Calls It ‘Unlawful Overreach’ — ‘The Results Are Preordained’
Yahoo - 2026-10-07
Novo Nordisk (NVO) or Eli Lilly (LLY)? Jim Cramer Gives a Clear Response
SeekingAlpha - 2026-10-07
Novo Nordisk Vs. Eli Lilly: Judged Against Big Pharma, Only One Needs A Premium
Yahoo - 2026-10-07
VKTX Advances Obesity Program With New Oral Maintenance Study
Yahoo - 2026-10-07
European Equities Traded in US as ADRs Fall in Wednesday Trading
Yahoo - 2026-10-07
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
Yahoo - 2026-10-06
Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
Yahoo - 2026-10-06
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
Yahoo - 2026-10-06
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
Yahoo - 2026-10-06
Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo - 2026-10-06
VKTX Down 16% in a Month: Time to Invest or Exit the Stock?
Yahoo - 2026-10-06
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?
SeekingAlpha - 2026-10-06
SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For October 2026
SeekingAlpha - 2026-10-06
Eli Lilly: Impressive Growth, Questionable Valuation
Yahoo - 2026-10-05
CN Bio Announces Expert Speaker Line-Up and Scientific Program for Inaugural Organ-on-a-Chip e-Symposium
Yahoo - 2026-10-05
Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
Yahoo - 2026-10-05
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
Yahoo - 2026-10-05
Novo Looks Beyond GLP-1s as Competition Intensifies
Yahoo - 2026-10-05
Novo Nordisk A/S – Share repurchase programme
Yahoo - 2026-10-05
FDA Extends Review of Novo Nordisk Haemophilia A Treatment Denecimig
Benzinga - 2026-10-05
FDA Delays Regulatory Decision On Novo Nordisk Hemophilia Drug
Yahoo - 2026-10-05
NVO vs. LLY: Novo’s CEO Says Confidence Is Gone. Lilly Is Winning 7 in 10 New Seniors.
Yahoo - 2026-10-04
Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?
Benzinga - 2026-10-03
Anthropic Commits $100 Million Behind AI Talent Push, Plans to Train 10,000 Engineers by 2027 as IPO Looms
Yahoo - 2026-10-02
Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals
Yahoo - 2026-10-02
Novo Nordisk Holds Its 2026 Outlook As FDA Review Of Its Blood Disorder Drug Runs Long
Yahoo - 2026-10-02
Novo provides update on the denecimig Biologics License Application (BLA) in the US
Yahoo - 2026-10-02
Novo Nordisk Strikes Nearly $4 Billion in 2 Deals. Here's What That Means for Investors
Yahoo - 2026-10-02
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo - 2026-10-02
DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care
Yahoo - 2026-10-02
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion
Benzinga - 2026-10-02
Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data
Yahoo - 2026-10-02
Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker
Yahoo - 2026-10-02
3 drug targets pharma is betting on next
Yahoo - 2026-10-02
LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies
SeekingAlpha - 2026-10-02
GLP-1s: Still Early In The Growth Story
Yahoo - 2026-10-01
How Eli Lilly Just Extended Its Lead in the Weight-Loss Drug Market
Benzinga - 2026-10-01
Over 88% Of Wegovy Trial Participants Achieve Normal Liver Fat Levels, Novo Reports
Yahoo - 2026-10-01
Novo's Wegovy Pill Shows Weight Loss After Switching From Injections
Yahoo - 2026-10-01
Eli Lilly obesity drug data adds pressure on Novo Nordisk
Yahoo - 2026-10-01
Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026
SeekingAlpha - 2026-10-01
Top 25 High-Growth Dividend Stocks For October 2026
SeekingAlpha - 2026-10-01
Top 25 Attractive Dividend Stocks For October 2026
Benzinga - 2026-10-01
Novo Announces Wegovy Liver Fat Reductions To Normal Levels In 9 Out Of 10 Adults With Obesity And Excess Liver Fat
Yahoo - 2026-09-30
Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy
Yahoo - 2026-09-30
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
Yahoo - 2026-09-30
NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk
Yahoo - 2026-09-30
3 Emerging Biotech Stocks With Significant Upside Potential
Yahoo - 2026-09-30
Eli Lilly stock rises on striking 23% weight loss in drug combo trial
Yahoo - 2026-09-30
Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?
SeekingAlpha - 2026-09-30
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More
Benzinga - 2026-09-30
10 Health Care Stocks With Whale Alerts In Today’s Session
Yahoo - 2026-09-30
4 Stocks That Could Split Next—and Why Investors Are Watching
Benzinga - 2026-09-30
Novo Nordisk Says Next-Gen Obesity Drug Reduces Food Noise, Drives Weight Loss
Yahoo - 2026-09-30
Novo Nordisk Wegovy pill weight loss switch study results
Yahoo - 2026-09-30
Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026
Yahoo - 2026-09-30
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
Benzinga - 2026-09-30
Tirzepatide or Semaglutide? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide (CORRECTED)
SeekingAlpha - 2026-09-30
Novo Nordisk: The Street Sold It For The Wrong Reason
Yahoo - 2026-09-29
Novo Nordisk (NVO) Dips More Than Broader Market: What You Should Know
Yahoo - 2026-09-29
Novo Nordisk (CPSE:NOVO B) Licensed A Once Weekly Oral GLP 1 GIP Drug
Yahoo - 2026-09-29
Lilly Says Higher-Dose Zepbound Just Widened Its Lead Over Wegovy
Yahoo - 2026-09-29
Prediction: Eli Lilly’s Next Growth Wave Could Surprise Investors
Yahoo - 2026-09-29
Lilly Stock Drops Lowwer Foundayo Claims an Oral Edge
Yahoo - 2026-09-29
Novo Nordisk Delivers Fresh Challenge to Eli Lilly With Ozempic Data
Yahoo - 2026-09-29
Novo Goes Shopping in China for Its Next Obesity Pill
Yahoo - 2026-09-29
Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects?
Benzinga - 2026-09-29
Tirzepatide or Wegovy? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide
SeekingAlpha - 2026-09-29
Novo Nordisk: After A 70+% Drop, It's A Great Investment
Benzinga - 2026-09-29
Wegovy or Zepbound? Eli Lilly Shows Zepbound Outperforms Wegovy in New Weight Loss Data
Yahoo - 2026-09-29
Hengrui Pharma shares rise as Novo Nordisk signs $2.6 billion drug deal
Yahoo - 2026-09-29
Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma
Yahoo - 2026-09-29
Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
Benzinga - 2026-09-28
Hengrui Pharma Signs Exclusive License With Novo For Once-Weekly Oral GLP-1/GIP Agonist HRS-1596, Featuring $300M Upfront In Up To $2.6B Deal
Yahoo - 2026-09-28
Can Novo Nordisk (NVO) Turn Monthly Dosing into Growth?
Yahoo - 2026-09-28
Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?
Yahoo - 2026-09-28
Eli Lilly Wavered Over the Last Month: One of Wall Street’s Biggest Banks Says 35% Gains Still to Come
Benzinga - 2026-09-28
Anthropic Claude’s Claimed Breakthrough in Biology Faces a Major Question — Scientist Says He Had Already Studied the Enzymes for 4 Years
Yahoo - 2026-09-27
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
Benzinga - 2026-09-27
Dexcom Becomes Team Novo Nordisk's Official CGM Partner, Releases Report Citing Three Type 2 Care Challenges Across Eight Countries
Yahoo - 2026-09-27
Can Novo Nordisk (NVO) Find a Second Act Before its First One Fades?
Yahoo - 2026-09-27
Novo’s Pipeline Strategy Takes Another Step Forward
Yahoo - 2026-09-27
Novo Nordisk Searches for Growth Beyond its Biggest Franchise
SeekingAlpha - 2026-09-27
Earn 10-15% Potential Income: Monthly Options Series (Oct. 2026)
Benzinga - 2026-09-26
'We Don't Know What the Risks Are': GLP-1 Pill Boom Fuels Hundreds of Apps, but Research Is Lagging
SeekingAlpha - 2026-09-25
InMode: Hope Is Not An Effective Investment Strategy, But Neither Is Despair
Yahoo - 2026-09-25
Could This Be Novo Nordisk’s Next Billion-Dollar Weight-Loss Product?
Yahoo - 2026-09-25
Viatris sues Novo Nordisk over generic Wegovy patent dispute
Yahoo - 2026-09-25
Novo Nordisk Changed the World With Its GLP-1 Weight-Loss Drugs. Now It Wants to Help Cure Baldness.
Yahoo - 2026-09-25
LLY's Onswik Wins FDA Nod as a Once-Weekly Basal Insulin for T2D
Benzinga - 2026-09-25
What's Going on With Novo Nordisk Stock on Friday?
Yahoo - 2026-09-25
Novo Nordisk's $1.3 Billion Deal Targets a Big Obesity-Drug Problem
Yahoo - 2026-09-25
Novo Pays Up to $1.3 Billion for Nanexa's Drug Delivery Tech
Yahoo - 2026-09-25
Novo Nordisk signs $1.3 billion deal for long-acting obesity shots
Yahoo - 2026-09-25
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Yahoo - 2026-09-25
Novo Nordisk Licenses Nanexa Drug-Delivery Technology in Deal Worth Up to €1.17 Billion
Yahoo - 2026-09-25
Nanexa shares rocket 114% on $1.3 billion Novo Nordisk licensing deal
Yahoo - 2026-09-25
Novo Signs $1.3 Billion Nanexa Deal for Long-Acting Drugs
Yahoo - 2026-09-24
Novo Nordisk's CEO delivered a warning that sank its stock by 8%
Yahoo - 2026-09-24
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
Yahoo - 2026-09-24
Novo Nordisk (NVO) Sets Pipeline Sales Target Above $23 Billion By 2035
Yahoo - 2026-09-24
European Equities Traded in the US as American Depositary Receipts Edge Lower in Thursday Trading
SeekingAlpha - 2026-09-24
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine
Yahoo - 2026-09-23
Novo Nordisk (NVO) Falls More Steeply Than Broader Market: What Investors Need to Know
Yahoo - 2026-09-23
Novo Nordisk CEO opens the door to major move for U.S. investors
Yahoo - 2026-09-23
NVO Stock On Track For Worst Week In Over 6 Months After Strategy Day — Direct US Listing Talks, Drug Approval Fail To Halt Slip
Yahoo - 2026-09-23
Novo's Oral Wegovy Just Revealed a Surprising Weight-Loss Signal
Yahoo - 2026-09-23
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
Benzinga - 2026-09-23
QUICK SPARK: Viking Therapeutics Stock Gains 40% in 2 Days
Yahoo - 2026-09-23
Novo Nordisk open to direct New York listing, CEO says
Yahoo - 2026-09-23
Huge News For Novo Nordisk Fans
Yahoo - 2026-09-23
Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial
Yahoo - 2026-09-23
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
Yahoo - 2026-09-23
VKTX Stock Rises on Encouraging Weight-Loss Maintenance Results
Yahoo - 2026-09-23
Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?
Yahoo - 2026-09-23
The Stock Market Is Sleeping on the Next Big AI Catalyst
Yahoo - 2026-09-23
U.S. demand for Novo Nordisk’s weight loss drugs is so huge that the Danish central bank just doubled the nation’s entire growth forecast
Yahoo - 2026-09-23
Novo Nordisk CEO Says Company Open to Direct NYSE Share Listing
SeekingAlpha - 2026-09-23
Launching The Allocation Compass: A Risk-Reward Approach To Portfolio Allocation
SeekingAlpha - 2026-09-23
Novo Nordisk: A Cheap Multiple Can't Fix Poor Growth
Yahoo - 2026-09-23
Novo Nordisk Gets Regulatory Nod in Singapore for Wegovy Treatment of Certain Liver Ailments
Benzinga - 2026-09-23
Anthropic, OpenEvidence Expand Free AI Clinical Tool to 100 Countries: Report
Benzinga - 2026-09-23
'Ozempic Maker Novo Open to Upgrading New York Listing' - FT
Yahoo - 2026-09-22
VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?
Yahoo - 2026-09-22
Novo Nordisk Just Made a Surprising Move Beyond Weight Loss
Yahoo - 2026-09-22
VKTX Stock Jumps 36% As Oppenheimer Hikes Target, Peers Call Data A Win
Yahoo - 2026-09-22
Beyond Eli Lilly and Novo Nordisk: Rising Obesity Drug Stocks to Watch
Yahoo - 2026-09-22
Roche's Enicepatide Shows Weight Loss, HbA1c Gains in Phase II Study
Yahoo - 2026-09-22
AstraZeneca and GSK warn Europe’s drug industry is ‘at risk’
Yahoo - 2026-09-22
Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results
Yahoo - 2026-09-22
European Markets Close Mixed Ahead of Trump-Xi Summit; Saudi Arabia Oil Pipeline Restarts
Yahoo - 2026-09-22
Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study
Yahoo - 2026-09-22
Company News for Sep 22, 2026
Yahoo - 2026-09-22
Roche Obesity Drug Enicepatide Delivers 15.5% Weight Loss in Phase 2 Diabetes Trial
Benzinga - 2026-09-22
3 Health Care Stocks With Whale Alerts In Today’s Session
Yahoo - 2026-09-22
VKTX Stock Spikes 38% Premarket: Viking’s VK2735 Shows Promise For Weight-Loss Maintenance
Yahoo - 2026-09-22
Novo and UNICEF expand partnership to support a healthier start for more than 80 million children
Yahoo - 2026-09-22
Novo's CEO Called Ozempic's Patent Cliff the "Elephant in the Room" Yesterday. Is the Stock Still a Buy?
Benzinga - 2026-09-22
Trump's Drug Price Achievements Questioned Following Separate Most Favored Nation Contract Disclosures with Lilly, Pfizer
Yahoo - 2026-09-22
VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’
Yahoo - 2026-09-21
Novo Nordisk (CPSE:NOVO B) Unveiled A 2030 Blockbuster Drug Plan
SeekingAlpha - 2026-09-21
Novo Nordisk A/S (NOVO:CA) Analyst/Investor Day Transcript
Yahoo - 2026-09-21
LLY Stock Gains As CEO Says Foundayo Wins One-Third of New GLP-1 Pill Starts, Breaks Ground On $6.5B Houston Plant
Yahoo - 2026-09-21
Sector Update: Healthcare Stocks Higher Late Afternoon
Yahoo - 2026-09-21
Lilly Gains as Novo Wins a Lower-Dose Weight-Loss Round
Yahoo - 2026-09-21
Novo Nordisk Targets Five Multi-Blockbusters by 2030 as Oral Wegovy Gains Traction
Yahoo - 2026-09-21
Why Novo Stock Is Tumbling After Drugmaker Unveils Ambitious Growth Plan
Yahoo - 2026-09-21
Sector Update: Healthcare Stocks Rise in Afternoon Trading
Yahoo - 2026-09-21
Why Novo Nordisk Stock Just Crashed
Yahoo - 2026-09-21
European Stocks Close Higher Monday as Oil Prices Tumble
Yahoo - 2026-09-21
Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations
Yahoo - 2026-09-21